News

DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

DANBIO is financially supported by grants from the Danish Rheumatism Association and the Danish Cancer Society. Dr. Hetland has acted as a consultant to Roche, and has received grants and research support on behalf of DANBIO from Abbott, BMS, Centocor, Roche, Schering-Plough, UCB-Nordic, and Wyeth. Dr. Dreyer had no disclosures. Dr. Schett was not involved in the study.

Pages

Recommended Reading

Juvenile Dermatomyositis Is Easily Missed Diagnosis
MDedge Dermatology
Platelet C4d Predicts Cardiovascular Events, Mortality in Lupus
MDedge Dermatology
Treating Psoriasis During Pregnancy Presents Unique Challenges
MDedge Dermatology
Ustekinumab 4-Year Data Show No Increased Cardiovascular Risk
MDedge Dermatology
Off-Label Uses for Biologics Growing
MDedge Dermatology
Rare Lymphoma Reports Continue in Young Patients on TNF Blockers
MDedge Dermatology
Anti-TNFs in Pregnancy Study Advises Continued Caution
MDedge Dermatology
Interrupting Biologics Possible, Not Ideal
MDedge Dermatology
TRACTISS to Study Rituximab Effects in Sjögren's Syndrome
MDedge Dermatology
Interaction Between Adalimumab With Concurrent Pregabalin and Duloxetine Administration in a Psoriasis Patient With Diabetic Peripheral Neuropathy [letter]
MDedge Dermatology